Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
Atypical Hemolytic-Uremic SyndromePost-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
0 and up
Participation Criteria
Inclusion Criteria:
* Male or female patients of any age, including minors, who have been diagnosed with aHUS
* Patients with or without an identified complement pathogenic variant or anti-complement factor antibody
* Able to give written informed consent. Patient or patient's parent/legal guardian must be willing and able to given written informed consent and the patient (if minor) must be willing to give written informed assent \[if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees (IRB/IEC)\].
* ADAMTS13 \> 5%, if performed.
Exclusion Criteria:
* Hemolytic Uremic Syndrome (HUS) only due to Shiga Toxin producing Escherichia coli (STEC).
* Unable to give written informed consent. Patient or patient's parent/legal guardian unable to give written informed consent. Patient (if minor) unable to give written informed assent (if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees \[IRB/IEC\]).
Study Location
Clinical Trial Site
Clinical Trial SiteToronto, Ontario
Canada
Contact Study Team
Licht
Clinical Trial Site
Clinical Trial SiteLondon, Ontario
Canada
Contact Study Team
Huang
Clinical Trial Site
Clinical Trial SiteMontréal, Quebec
Canada
Contact Study Team
Lapeyraque
Clinical Trial Site
Clinical Trial SiteQuébec, Quebec
Canada
Contact Study Team
Philibert
- Study Sponsored By
- Alexion Pharmaceuticals, Inc.
- Participants Required
- More Information
- Study ID:
NCT01522183